AHA 2019 | DAPA-HF: Dapagliflozin Effective for all Heart Failure Subgroups

SGLT2 inhibitor dapagliflozin had a consistent impact regardless of glycemic level, age, or general health status.

AHA 2019 | DAPA-HF: la dapagliflozina efectiva en todos los subgrupos con insuficiencia cardíaca

Dapagliflozin was originally developed for the treatment of type 2 diabetes. However, it has had a positive impact on various types of patients with chronic heart failure and reduced ejection fraction, including those without diabetes. This information is derived from the DAPA-HF trial, presented at the American Heart Association (AHA) 2019 Congress Scientific Sessions and simultaneously published in Circulation.

The initial trial results were presented in September at the European Society of Cardiology Congress in Paris. At the time, we found out that patients with and without type 2 diabetes benefited from dapagliflozin associated with optimized standard therapy.


Read also: AHA 2019 | COLCOT: Colchicine and the Return of the Anti-Inflammatory Theory.


Now, at the AHA sessions, researchers presented new outcomes that dug deeper into nondiabetic patients and patients in different age groups.

DAPA-HF was conducted in 20 countries and randomized 4744 patients with New York Heart Association functional class II or greater heart failure, ejection fraction of 40% or lower, and NT-proBNP of 600 pg/mL or higher.

At a mean follow-up of 18 months, the addition of 10-mg dapagliflozin to the standard of care reduced the risk for the composite endpoint of worsening heart failure or death for cardiovascular causes (16.3% vs. 21.2%; hazard ratio [HR]: 0.74; 95% confidence interval [CI]: 0.65-0.85).

Such benefit was consistent across all glycated hemoglobin levels in patients without diabetes.


Read also: AHA 2019 | TWILIGHT: Discontinue Aspirin after Acute Coronary Syndrome.


As regards elderly patients, the benefit derived seems even higher than for younger patients, without additional tolerability problems.

Dapagliflozin seems to fulfill all goals of heart failure management, reducing mortality and hospitalizations, and improving NYHA functional class in all patients.

dapa-hf-aha2019

dapa-hf-aha2019-2

Original Title: The dapagliflozin and prevention of adverse outcomes in heart failure trial (DAPA-HF): results in nondiabetic patients.

Reference: Presentado por McMurray JJV en las sesiones científicas del congreso AHA 2019.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...